The Functions of Cytochrome P450 ω-hydroxylases and the Associated Eicosanoids in Inflammation-Related Diseases

The cytochrome P450 (CYP) ω-hydroxylases are a subfamily of CYP enzymes. While CYPs are the main metabolic enzymes that mediate the oxidation reactions of many endogenous and exogenous compounds in the human body, CYP ω-hydroxylases mediate the metabolism of multiple fatty acids and their metabolites via the addition of a hydroxyl group to the ω- or (ω-1)-C atom of the substrates. The substrates of CYP ω-hydroxylases include but not limited to arachidonic acid, docosahexaenoic acid, eicosapentaenoic acid, epoxyeicosatrienoic acids, leukotrienes, and prostaglandins. The CYP ω-hydroxylases-mediated metabolites, such as 20-hyroxyleicosatrienoic acid (20-HETE), 19-HETE, 20-hydroxyl leukotriene B4 (20-OH-LTB4), and many ω-hydroxylated prostaglandins, have pleiotropic effects in inflammation and many inflammation-associated diseases. Here we reviewed the classification, tissue distribution of CYP ω-hydroxylases and the role of their hydroxylated metabolites in inflammation-associated diseases. We described up-regulation of CYP ω-hydroxylases may be a pathogenic mechanism of many inflammation-associated diseases and thus CYP ω-hydroxylases may be a therapeutic target for these diseases. CYP ω-hydroxylases-mediated eicosanods play important roles in inflammation as pro-inflammatory or anti-inflammatory mediators, participating in the process stimulated by cytokines and/or the process stimulating the production of multiple cytokines. However, most previous studies focused on 20-HETE,and further studies are needed for the function and mechanisms of other CYP ω-hydroxylases-mediated eicosanoids. We believe that our studies of CYP ω-hydroxylases and their associated eicosanoids will advance the translational and clinal use of CYP ω-hydroxylases inhibitors and activators in many diseases.


INTRODUCTION
Cytochrome P450 (CYP) enzymes, discovered in the early 1960s, are a superfamily of heme containing membrane bound monoxygenases which is available in microorganisms, plants, animals, and humans (Guengerich et al., 2016;Elfaki et al., 2018). About 300,000 CYP sequences have been collected from public and private sources (Nelson, 2018). The common reactions catalyzed by CYPs include hydroxylation, heteroatom oxygenation and release, epoxidation, and oxidation of double, triple, or aromatic π-bonds (Guengerich, 2001;McIntosh et al., 2014;Ortiz de Montellano, 2019). Mammalian CYP enzymes are distributed in a variety of tissues and organs of organisms, and play a core role in cell metabolism to maintain cell homeostasis mainly by mediating the metabolism of a large number of xenobiotic and endobiotic molecules, including but not limited to drugs, industrial toxins, steroids, cholic acid, and fatty acids through regio-, chemo-and stereospecific oxidation, peroxidation and reduction (Urlacher and Girhard, 2012;Manikandan and Nagini, 2018). There are 57 CYP genes and 58 pseudogenes in human and are divided into 18 families and 43 subfamilies (Waring, 2020), which are mainly present in the kidney, small intestine and liver tissues (Elfaki et al., 2018). The CYP ω-hydroxylases, are a group of subfamilies of CYPs that mediate the metabolism of multiple fatty acids via the addition of a hydroxyl group to the ωor (ω-1)-C atom of the substrates. This includes polyunsaturated fatty acids (PUFAs), such as arachidonic acid (AA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and their derivatives (Figure 1). Those metabolites derived from AA, EPA and DHA are the members of eicosanoids and function as inflammatory mediators, which play an important role in the occurrence and progression of many pathological conditions like cardiovascular disease, cancer and diabetes (Westphal et al., 2011;Schunck et al., 2018;Colombero et al., 2020). This article reviews the activity FIGURE 1 | Simplified cascade of CYP ω-hydroxylases-mediated substrates and associated metabolites. The compounds with the same color indicate they are derived from the same substrates. AA, arachidonic acid; AS, N-arachidonoylserine; COX, cyclooxygenase; CYP, cytochrome P450; DHA, docosahexaenoic acid; EET, epoxyeicosatrienoic acid; EEQ, epoxyeicosatetreaenoic acid; EDPs, epoxydocosapentaenoic acid; EPA, eicosapentaenoic acid; HEPEs, hydroxyeicosapentaenoic acid; HEETs, hydroxyepoxyeicosatrienoic acids; HPDHA, hydroperoxydocosahexaenoic acid; HpEPE, hydroperoxyeicosapentaenoic acid; HETE, hydroxyeicosatetraenoic acid; HDoHE, hydroxydocosahexaenoic acid; LOX, lipoxygenase; LTA 4 , leukotriene A 4 ; LTB 4, leukotriene B 4; PGH 2 , prostaglandin H 2 ; PGE 3 , prostaglandin E 3 . and expression changes of CYP ω-hydroxylase in inflammationrelated diseases, and the enzyme-mediated metabolites, such as 20-HETE, which trigger the downstream signaling pathway and induce more pathological changes.
The CYP4A subfamilies are found in mammals, including human, rat, and mice, and are mainly expressed in the liver and kidney (Simpson, 1997). The mouse Cyp4a subfamily includes Cyp4a10, Cyp4a1a, Cyp4a12b, and Cyp4a14. In mice, Cyp4a mRNA expression levels in the liver and kidney are regulated by sex hormones and/or growth hormones (Zhang and Klaassen, 2013). In human, there are two highly homologous CYP4A genes (CYP4A11 and CYP4A22) located on chromosome 1, and showed 96% sequence identity (Bellamine et al., 2003;Savas et al., 2003;Hsu et al., 2007). However, rat CYP4 has four members (genes Cyp4a1, Cyp4a2, Cyp4a3, and Cyp4a8). CYP4A subfamily proteins metabolize arachidonic acid to produce 19hydroxyeicosatetraenoic acid (19-HETE) and 20-HETE, playing an important role in lipid homeostasis related to fatty acids and eicosanoic acids. Several studies have shown that CYP4A11 contributes about 13 and 33% to the formation of 20-HETE by ω-hydroxylation of arachidonic acid in the human liver and kidney (Powell et al., 1998;Lasker et al., 2000). The functions of the CYP4A22 have not been elucidated fully. The tissue distribution of CYP4B1 varies widely among species. Cyp4b1 was originally discovered from the rabbit lung in the mid-1970s (Arinç and Philpot, 1976). In mice, Cyp4b1 expression is predominantly present in the brain, lung, and small intestine, while low in the spleen, testis, liver, and skeletal muscle (Baer and Rettie, 2006). Human CYP4B1 is mainly found in lung microsomes, accounting for 70% of the total, and remaining parts in the heart, skeletal muscle, kidneys, and prostate glands (Choudhary et al., 2005). CYP4B1 is specialized in the ω-hydroxylation of short-chain fatty acids and the metabolism of exogenous compounds including valproic acid, 3-methylindole, 4-ipomeanol, 3-methoxy-4-aminoazobenzene, and many aromatic amines ( Figure 1B) (Baer and Rettie, 2006). The tissue specificity, genetic polymorphisms, and metabolic capabilities of human CYP4B1 are still under investigation because of the difficulty in allogeneic expression of the human CYP4B1 gene.
Human has seven CYP4F enzymes encoded by six different genes in the CYP4F gene cluster (19p13.1) on chromosome 19. CYP4F2 enzyme, also known as leukotriene B 4 (LTB 4 ) omegahydroxylase, is located on chromosome 19 p13.11. CYP4F2 is approximately 20 kbp, consisting of 13 exons and 12 introns encoding 520 amino acids (Kikuta et al., 1999). It is mainly distributed in tissues and organs such as liver, kidney, lung, white blood cells, and particularly endoplasmic reticulum (Hsu et al., 2007;Hirani et al., 2008). CYP4F2 is a monooxygenase that catalyzes many reactions, including drug metabolism, the synthesis and metabolism of lipids, steroids, and cholesterol. It can affect the metabolism of AA and catalyze LTB 4. , a metabolite of AA mediated by (5-LOX), serving as the main ω-hydroxylase of AA and LTB 4 . Eun et al. found that the mRNA expression levels of CYP4F2 and CYP4F12 in hepatocellular carcinoma tissues were significantly lower than those in normal liver tissues, which was closely related to the overall survival rate of patients with hepatocellular carcinoma (Eun et al., 2018). CYP4F3, an unusual human CYP gene, was initially identified as the ω-oxidase that catalyzes LTB 4 in human neutrophils (Shak and Goldstein, 1984;Kikuta et al., 1993;Christmas et al., 2001). Christmas et al. subsequently identified an alternative splice form of CYP4F3 in the liver and specified two subtypes, CYP4F3A and CYP4F3B (Christmas et al., 2001). CYP4F3A is expressed in neutrophils but not in the liver and has a very high affinity to LTB 4 . In contrast, CYP4F3B is mainly expressed in the human liver and kidney, but not in myeloid cells, which is more active in the hydroxylation of AA and other ω-3 polyunsaturated fatty acids (PUFA) than in hydroxylating LTB 4 (Fer et al., 2008). In rat, Cyp4f6 converts LTB 4 to form 19-and 18-hydroxy-LTB 4 with an apparent K(m) of 26 M and Cyp4f5 converts LTB 4 predominantly to 18-hydroxy-LTB 4 with an apparent K(m) of 9.7 M ( Figure 1C). CYP4F5 and CYP4F6 are active in the lung and to some extent in the brain, kidney and testis. CYP4F5 and CYP4F6, due to their ability to metabolize LTB 4 , may play an important role in regulating the inflammatory response in these organs (Bylund et al., 2003).
Human CYP4V2 protein is expressed in eye, ovary, and liver (Li et al., 2004), while mouse Cyp4v3 is mainly detected in the liver and retina (Jenkins et al., 2006;Liu et al., 2006). Human CYP4X1 is very widely expressed transcriptionally in adult human tissues, predominantly in skeletal muscle, trachea, and aorta (Hsu et al., 2007). Al-Anizy et al. reported that Cyp4x1 was a major CYP protein in mouse brain (Al-Anizy et al., 2006). CYP4Z1 gene is a unique CYP4 gene in human, and no orthologous gene has been found in mice at present. CYP4Z1 is mainly distributed in human liver, kidney, skeletal muscle, testis, and mammary, and is highly expressed in breast cancer, and a regulator of tumor angiogenesis and growth of breast cancer (Yu et al., 2012;Wang et al., 2016;Nunna et al., 2017;Yang et al., 2017). The substrates of CYP4Z1 and associated metabolism have not been fully understood. CYP2U1 is an "orphan" enzyme which was originally identified as a member of CYP2 subfamily by Chuang et al. (2004) and Karlgren et al. (2004). To date, the CYP2U1 gene, the only reported member of the CYP2U subfamily, is over 18 kb long and located on chromosome 4q25 (Devos et al., 2010). Human CYP2U1 shares 89 and 83% amino acid sequence identity with rat and mouse Cyp2u1, respectively (Dhers et al., 2017). Studies have shown that human CYP2U1 mRNA is expressed predominantly in thymus and cerebellum, and similar findings were observed in rat and mice (Chuang et al., 2004;Karlgren et al., 2004;Dhers et al., 2017). However, human CYP2U1 protein was only detected in brain, platelets and megakaryocytic Dami cells (Dhers et al., 2017). Likewise, in rat Cyp2u1 protein was also present only in the cerebellum and thymus (Karlgren et al., 2004). CYP2U1 showed hydroxylase activity for fatty acids and N-arachidonoylserine (AS) ( Figure 1D) (Dhers et al., 2017). Although CYP2U1 has been shown to be involved in some diseases such as breast cancer and hereditary spastic paraplegia, the biological role is still largely unknown . The cell-specific distribution of CYP ω-hydrolases is key to the local pro-inflammatory effects observed across various diseases. While a systemic study of the cell-specific distribution of these enzymes was lacked, CYP4A, CYP4F, and CYP4B1 have been frequently investigated in epithelial cells, endothelial cells, platelet and immunocytes ( Table 1) (Kikuta et al., 2002;Kikuta et al., 2004;Cheng et al., 2014;Li et al., 2015;Chen et al., 2019).

ORTHOLOGOUS CYTOCHROME P450 ω-HYDROXYLASE GENES IN HUMAN AND MICE
Many different species share homology of genes. Generally, two genes are homologous genes when their sequence similarities are Frontiers in Pharmacology | www.frontiersin.org September 2021 | Volume 12 | Article 716801 over 80%. Homologous sequences can be further divided into two types: orthology and paralogy (Koonin, 2005). A recent study showed that 84% of mouse-human orthologous genes have been conservatively evolved in the expression profiles (Hrycay and Bandiera, 2009). Thirty six pairs of orthologous CYP genes have been found to perform similar or identical functions in human and mice, which facilitates to study the functions of human CYPs by using murine models (Nelson et al., 2004). The CYP ω-hydroxylase orthologous genes in human and mice are shown in Table1.

EFFECTS OF GENDER ON CYTOCHROME P450 ω-HYDROXYLASE
The expression of CYP ω-hydroxylases has gender differences. Cyp4a10 is expressed in both male and female mice, while Cyp4a12a is male-specific and regulated by androgen, and Cyp4a14 is strongly expressed in female mice (Wu et al., 2013). Cyp4a14 (−/−) mice have been found to exhibit malespecific hypertension. Whereas administration of androgens to male or female rat or mice results in hypertension (Holla et al., 2001). Both 20-HETE and androgens have been found to be strongly associated with hypertension and other cardiovascular diseases (Reckelhoff, 2005;Ward et al., 2005). However, the connection and potential mechanism between Both 20-HETE and androgens have not been clarified.

CYTOCHROME P450 ω-HYDROXYLASES AND INFLAMMATION
CYP4A, CYP4B, CYP4F, and CYP2U1 are the subfamilies of CYP ω-hydroxylases that catalyze the hydroxylation of AA, other medium-and long-chain fatty acids, and the derivatives of fatty acids like LTB 4, EETs, and prostaglandins. The CYP ω-hydroxylases-mediated metabolites derived from abovementioned substrates, particularly 20-HETE, have been shown to play a vital role in inflammatory diseases. Here, we discuss the role of CYP ω-hydroxylases in inflammation.
Recent studies have shown that inflammation could significantly decrease the expression of CYP monooxygenases in the heart, kidney, and liver, while increase the expression of CYP ω-hydroxylases. As a result, CYP ω-hydroxylase mediated conversion of the corresponding metabolites of EETs were decreased, while 20-HETE was increased. These changes may participate in the onset and progression of various diseases through inflammatory response (Anwar-mohamed et al., 2010). In an in-vivo study, salidroside can facilitate reprogramming of CYP4A-mediated arachidonic acid metabolism in macrophages in the treatment of monosodium urate crystal-induced gouty arthritis. The study reported that salidroside could reduce the production of inflammatory factors TNF-α and IL-1β by down-regulating CYP4A to polarize macrophages away from the M1 phenotype, and ameliorate inflammation . Ashkar et al. found that retinoic acid induces corneal epithelial CYP4B1 gene expression and stimulates the synthesis of inflammatory 12hydroxyeicosanoic acid (Ashkar et al., 2004).
In a rodent model of lipopolysaccharide (LPS)-induced inflammatory infection and injury, the mRNA expressions of Cyp4f4 and Cyp4f5 were decreased by 50 and 40%, respectively, in the liver, while the concentrations of leukotrienes and prostaglandins were increased. When Cyp4f was up-regulated, leukotrienes and prostaglandin mediators were decreased, thus alleviating inflammation (Cui et al., 2003). The decrease in leukotrienes and prostaglandins caused by upregulation of Cyp4f may be accounted for the metabolic shunting among CYPs, COXs, and LOXs, and/or Cyp4f-mediated metabolism of leukotrienes and prostaglandins. In addition, Kalsotra et al. reported that in a rat model of traumatic brain injury, inflammatory cells in the airway and alveolar space migrated extensively, and further secondary damage could be relieved by reducing LTB 4 via activating LTB 4 decomposition by induced CYP4Fs, which opened up new possibilities for the treatment of post-traumatic pulmonary inflammation (Kalsotra et al., 2007b). CYP4F2, the major LTB 4 hydroxylase expressed in human liver, may play an important role in regulating the circulation and liver levels of LTB 4 (Johnson et al., 2015). In addition to LTB 4 , it was also found that lipoxin A4 (LXA 4 ) and hydroxyeicosanoic acid in rodent hepatocytes could be degraded via the ω-hydroxylation by recombinant CYP4Fs. Proinflammatory cytokines, such as IL-1β, IL-6, and TNF-α, induce CYP4Fs via STAT3 signaling. The anti-inflammatory factor IL-10 inhibits the expression of CYP4F (Kalsotra et al., 2007a).
With the continuous innovation and development of biotechnology, research tools of chemical synthesis and gene editing continue to expand, research efficiency of CYP ω-hydroxylase is greatly improved. The associations of CYP ω-hydroxylases with pathogenesis of diseases are gradually discovered. Currently, activators and inhibitors of CYP ω-hydroxylase isomers, and CYP ω-hydroxylase knockout (KO) and transgenic mice are gradually being utilized in many studies. Tables 2, 3 summarizes the commonly used inhibitors and inducers of CYP ω-hydroxylase and CYP ω-hydroxylase KO and transgenic mice models.

THE ROLES OF CYTOCHROME P450 ω-HYDROXYLASE-MEDIATED EICOSANOIDS IN INFLAMMATION-ASSOCIATED DISEASES
Eiconanoids have different modulating inflammation effects on cardiovascular system, brain, liver, and lung during pathological condition. Here, we summarized the effects of eiconanoids on inflammatory diseases in different tissues (Table 4). When these organs are damaged by inflammation caused by a variety of pathogenic factors, excessive inflammatory mediators including eicosanoids will be released locally, which can mediate the inflammatory reactions in local tissues (Wallace, 2019;Yao and Narumiya, 2019;Calder, 2020). 20-HETE is the major metabolite of arachidonic acid mediated by CYP ω-hydroxylase, which plays an important role in the regulation of cardiovascular disease, renal function disorder, carcinogenic condition, and other inflammatory diseases. CYP4A11 and CYP4F2 are the primary enzymes that mediate the formation of 20-HETE in human liver and kidney microsomes (Lasker et al., 2000). Vascular inflammation plays an important role in the occurrence of many diseases, including atherosclerosis, hypertension, and vascular remodeling. 20-HETE can promote vascular inflammation by increasing adhesion molecules and inflammatory cytokines due to endothelial cell activation (Hoopes et al., 2015). 20-HETE can activate nuclear factor-kappa B (NF-κB) and stimulate the production of inflammatory cytokines in human endothelial cells (Ishizuka et al., 2008). Recent studies have proved that 20-HETE could bind to the G-protein coupled receptor 75 (GPR75) to promote c-Src-mediated-EGFR and trigger the downstream MAPK pathway to induce ACE expression and endothelial dysfunction in human endothelial cells (Garcia et al., 2017;Pascale et al., 2021). 20-HETE/GPR75 also triggered PI3K/ AKT pathway to promote vascular smooth muscle cells migration, hypertrophy. Moreover, 20-HETE/GPR75 is involved in the activation of intracellular signaling in prostate cancer cells, leading to the more aggressive phenotypic

CYTOCHROME P450 ω-HYDROXYLASE-MEDIATED PRODUCTS OF LTB 4
LTB 4 is an inflammatory mediator involved in inflammatory diseases such as rheumatoid arthritis, asthma and Alzheimer's disease, which can be metabolized by CYP4F2, CYP4F3A and CYP4F3B to form 20-OH-LTB 4 (Kalsotra and Strobel, 2006) (Lorenzetti et al., 2019) (Brain and Williams, 1990;Wang et al., 2008). LTB4 is converted by CYP4F to the more polar 20-OH-LTB 4 in human polymorphonuclear leukocytes (PMN) (Soberman et al., 1988). However, 20-OH-LTB 4 expressed similar functional activity to LTB 4 , and similar binding characteristics with human PMN to LTB 4 . This indicated that the arachidonic acid metabolite oxidized at ω-site of LTB 4 may be a more important inflammatory factor than LTB 4 (Clancy et al., 1984). Analysis of peritoneal metabolites in patients with purulent peritonitis or non-performatives appendicitis revealed that 20-OH-LTB 4 might be involved in the pathophysiological mechanisms of suppurative inflammation (Kikawa et al., 1986). A recent study showed that 20-OH-LTB 4 might function as a potential biomarker for the diagnosis and risk assessment of intracerebral hemorrhage stroke (ICH) to distinguish the patients with ICH from healthy people and the patients with acute ischemic stroke (AIS). This finding provides a new strategy for the diagnosis, prevention and treatment of ICH (Zhang et al., 2021). In mouse myeloid cells, Cyp4f18 (the functional orthologue of human PMN CYP4F3A) catalyzes the conversion of LTB 4 to 19-OH-LTB 4 . Inhibition of Cyp4f18 led to a 220% increase in the PMN chemotaxis to LTB 4 in mice (Christmas et al., 2006). While the ω-hydroxylated products of LTB 4 play different physiological roles in some diseases, the mechanisms in inflammation are still unclear, which needs further study.

CYTOCHROME P450 ω-HYDROXYLASE-MEDIATED PRODUCTS OF PROSTAGLANDINS
Since 1971, a series of studies have identified the Cyp4a hydroxylase family from multiple organs in rabbit and mouse liver (Kikuta et al., 2002). These enzymes catalyze the hydroxylation of multiple prostaglandins (PGE 1 , PGE 2 , PGF 2 , PGD 2 , PGA 1 , and PGA 2 ) as well as ωand (ω-1)-hydroxylation of palmitate. In humans, CYP4A11 can hydroxylate three PGH 2 analogs (U51605, U44069, U46619), although it cannot hydroxylate PGH 2 (Oliw et al., 2001). Moreover, PGH 2 could be converted by CYP4F8 into 19(R)-OH-PGH 2 in prostate, seminal vesicles, and several extrahepatic tissues (Oliw et al., 1988;Hardwick, 2008). PGE 2 is closely related to the production of cytokines in antigen presenting cells and plays an important role in the stage of inflammatory regression, while 19(R)-OH-PGE 2 is an agonist of PGE 2 receptor (Serhan et al., 2007). At present, PGs have been studied extensively but little is known about the function of their hydroxylated products, and further studies are required to determine the function in various tissues and species.

CYTOCHROME P450 ω-HYDROXYLASE-MEDIATED EICOSANOIDS AND CYTOKINES
CYP ω-hydroxylase-mediated eicosanoids are also involved in the regulation of cytokines, especially 20-HETE in cardiovascular inflammation has been widely studied. Cheng et al. found that 20-HETE could mediate the endothelial nitric oxide synthase (eNOS) uncoupling and endothelial dysfunction through activating tyrosine kinase, MAPK and IKK in bovine aortic endothelial cells (Cheng et al., 2010). In addition, 20-HETE can also stimulate NF-κB and MAPK/ERK to increase protein expression levels of IL-8 and adhesion molecule ICAM, leading to endothelial cell activation (Ishizuka et al., 2008;Cheng et al., 2010). In the spontaneously hypertensive rat model, the inhibition of 20-HETE by HET006 (CYP ω-hydroxylase inhibitor) could significantly reduce oxidative stress and the mRNA expression of TNFα and IL-1β, and the NF-κB activation (Toth et al., 2013). Cheng et al. developed a new constitutively stimulated 20-HETE biosynthesis mouse model, the Tie2-CYP4F2-Tr mouse. By activating the NADPH oxidase and VEGF pathway, the model has the phenotypic characteristics of oxidative stress, increased expression of NADPH oxidase and IL-6, and increased cell proliferation and angiogenesis, which can be used to further study the physiopathological effect of 20-HETE in the cardiovascular system .

CONCLUSION
CYP ω-hydroxylase and metabolite have been reported to play an important role in the inflammatory process (Figure 2). In a variety of inflammatory diseases, the activity of CYP ω-hydroxylase is regulated by inflammatory factors. Proinflammatory cytokines, IL-1β, IL-6 and TNF-α, can increase CYP ω-hydroxylase activity, whereas anti-inflammatory cytokines such as IL-10 can inhibit CTP hydroxylase expression. Therefore, the production of metabolites of these hydroxylases are affected accordingly. At present, a large number of studies showed that 20-HETE could modulate inflammatory processes ( Figure 3). However, little is known about the role of other CYP hydroxylated products in inflammation. 20-HETE can increase the production of adhesion molecules and inflammatory cytokines as well as ROS level through the activation of NF-κB, MAPK pathway, and NADPH oxidase, to activate endothelial cell activation, promote cell proliferation and regulate endothelial dysfunction. The accumulation of inflammatory factors will also affect the activity of CYP ω-hydroxylases to promote the metabolism of eicosanoids and form a positive feedback regulation, further affecting the progress of cardiovascular diseases, cancer, inflammation and other diseases. Elucidation of the effects of inflammation and infection on the metabolism of CYP hydroxylase and eicosanoids and the relationship between specific cytokines and their mediated of CYP enzymes will help in-depth understanding about the pathogenesis of many diseases and update therapeutic strategies. However, due to the complexity of the cytokines involved in the inflammatory process and their signaling pathways, there has not been a consensus on its potential mechanism. Regulation of the expression or activity of CYP ω-hydroxylase may play a role in the treatment of inflammatory diseases. For the translational and clinical research of CYP-ω-hydroxylase, inducers and inhibitors of CYP-ω-hydroxylase may be novel therapeutic strategies for many clinical inflammatory diseases. In addition, CYP-ω-hydroxyase also could be used as the marker for the diagnosis of related difficult and complicated diseases, improving the existing diagnostic methods. Therefore, more researches are needed to further clarify the mechanism of CYP ω-hydroxylase to advance the translational and clinical studies of CYP ω-hydroxylases.